Future therapies in melasma: What lies ahead?

Area of Science:

• Dermatology
• Pathophysiology
• Pharmacology

Background:

• Melasma is a common skin condition causing symmetrical hyperpigmentation.
• It significantly impacts patient quality of life and is challenging to treat.
• Current understanding views melasma as a complex interplay of epidermal and dermal cells, influenced by inflammation, UV radiation, genetics, and hormones.

Purpose of the Study:

• To review current understanding of melasma pathogenesis.
• To explore novel therapeutic targets and agents for melasma treatment.
• To discuss the potential of future combination therapies.

Main Methods:

• Literature review of melasma pathogenesis and treatment strategies.
• Analysis of emerging therapeutic agents and their mechanisms of action.
• Discussion of the role of botanicals, oral agents, and combination therapies.

Main Results:

• Melasma involves melanocytes, keratinocytes, fibroblasts, mast cells, and vascular cells.
• Effective treatments must address factors beyond melanin synthesis, including inflammation, oxidative stress, and vasculature.
• Newer agents, often botanicals, target these factors with improved safety profiles.
• Oral agents like tranexamic acid and ascorbic acid show promise.

Conclusions:

• Melasma treatment requires a multimodal approach targeting various contributing factors.
• Botanical agents and oral therapies offer promising alternatives with better safety.
• Future melasma management may involve combination therapies targeting multiple pathways, such as hydroquinone, antiestrogens, and VEGF inhibitors.